Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$15.93 +0.8%	$16.43	$9.57 ▼ $27.34	$2.18B	0.93	2.04 million shs	1.52 million shs
BEAM Beam Therapeutics	$18.83 -4.5%	$18.67	$13.52 ▼ $35.25	$1.98B	2.22	2.37 million shs	2.71 million shs
TBPH Theravance Biopharma	$10.90 -2.3%	$10.86	$7.44 ▼ $11.88	$558.02M	0.01	154,642 shs	202,568 shs
TWST Twist Bioscience	$33.68 +0.3%	$34.67	$27.12 ▼ $55.33	$2.01B	2.37	891,336 shs	1.38 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+0.82%	+1.21%	-5.74%	+10.47%	-44.22%
BEAM Beam Therapeutics	-4.46%	-13.31%	-5.28%	-6.97%	-40.49%
TBPH Theravance Biopharma	-2.33%	-1.18%	-1.36%	+5.11%	+7.81%
TWST Twist Bioscience	+0.33%	-6.42%	-10.62%	-14.17%	-39.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.8355 of 5 stars	3.4	2.0	3.4	3.8	1.7	0.0
BEAM Beam Therapeutics	2.6099 of 5 stars	3.5	1.0	0.0	3.2	2.5	0.6
TBPH Theravance Biopharma	1.814 of 5 stars	3.3	2.0	0.0	0.0	2.5	0.6
TWST Twist Bioscience	3.5578 of 5 stars	3.4	0.0	4.4	3.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.89	Moderate Buy	$43.71	174.41% Upside
BEAM Beam Therapeutics	3.07	Buy	$48.75	158.90% Upside
TBPH Theravance Biopharma	2.67	Moderate Buy	$16.60	52.29% Upside
TWST Twist Bioscience	2.70	Moderate Buy	$50.40	49.64% Upside

Current Analyst Ratings Breakdown

Latest TBPH, BEAM, ARWR, and TWST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2025	ARWR Arrowhead Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/21/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/27/2025	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$24.00 ➝ $25.00
6/17/2025	TBPH Theravance Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$24.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00
5/6/2025	TWST Twist Bioscience	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$545.21M	4.04	N/A	N/A	$1.54 per share	10.34
BEAM Beam Therapeutics	$63.52M	29.81	N/A	N/A	$8.86 per share	2.13
TBPH Theravance Biopharma	$64.38M	8.47	N/A	N/A	$3.57 per share	3.05
TWST Twist Bioscience	$312.97M	6.45	N/A	N/A	$8.07 per share	4.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	18.58	N/A	-45.33%	-12.49%	8/7/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
TBPH Theravance Biopharma	-$56.42M	-$1.18	N/A	31.14	N/A	-89.38%	-32.37%	-16.48%	8/4/2025 (Estimated)
TWST Twist Bioscience	-$208.73M	-$3.25	N/A	N/A	N/A	-54.98%	-33.48%	-25.34%	8/4/2025 (Confirmed)

Latest TBPH, BEAM, ARWR, and TWST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	TBPH Theravance Biopharma	-$0.12	N/A	N/A	N/A	$16.04 million	N/A
8/7/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	N/A	N/A	N/A	$29.01 million	N/A
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	N/A	N/A	N/A	$13.29 million	N/A
8/4/2025	Q3 2025	TWST Twist Bioscience	-$0.54	N/A	N/A	N/A	$95.52 million	N/A
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/8/2025	Q1 2025	TBPH Theravance Biopharma	-$0.11	-$0.27	-$0.16	-$0.27	$28.08 million	$15.39 million
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/5/2025	Q2 2025	TWST Twist Bioscience	-$0.56	-$0.66	-$0.10	-$0.66	$92.00 million	$92.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A
TWST Twist Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
BEAM Beam Therapeutics	N/A	8.81	8.81
TBPH Theravance Biopharma	N/A	4.77	4.77
TWST Twist Bioscience	0.03	4.51	4.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BEAM Beam Therapeutics	99.68%
TBPH Theravance Biopharma	99.10%
TWST Twist Bioscience	N/A

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
BEAM Beam Therapeutics	3.50%
TBPH Theravance Biopharma	6.90%
TWST Twist Bioscience	3.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
TBPH Theravance Biopharma	110	50.00 million	46.55 million	Optionable
TWST Twist Bioscience	990	59.92 million	58.11 million	Optionable

TBPH, BEAM, ARWR, and TWST Headlines

Recent News About These Companies

Preview: Twist Bioscience's Earnings

3 hours ago | benzinga.com

Twist Bioscience Corporation (NASDAQ:TWST) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 1 at 2:39 AM | americanbankingnews.com

Twist Bioscience Expands In Vivo Antibody Discovery Services with Launch of Humanized Transgenic Mouse Model

July 31 at 6:52 PM | finance.yahoo.com

Is There An Opportunity With Twist Bioscience Corporation's (NASDAQ:TWST) 27% Undervaluation?

July 31 at 4:52 AM | finance.yahoo.com

Is Twist Bioscience Corp. (TWST) Nearing Profitability?

July 28, 2025 | msn.com

Twist Bioscience (TWST) to Release Earnings on Monday

July 28, 2025 | marketbeat.com

Envestnet Asset Management Inc. Has $2.76 Million Position in Twist Bioscience Corporation (NASDAQ:TWST)

July 28, 2025 | marketbeat.com

ARK Investment Management LLC Acquires 645,730 Shares of Twist Bioscience Corporation (NASDAQ:TWST)

July 27, 2025 | marketbeat.com

Nikko Asset Management Americas Inc. Sells 197,166 Shares of Twist Bioscience Corporation (NASDAQ:TWST)

July 27, 2025 | marketbeat.com

Baillie Gifford & Co. Has $28.74 Million Holdings in Twist Bioscience Corporation (NASDAQ:TWST)

July 27, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) Given Average Recommendation of "Moderate Buy" by Brokerages

July 27, 2025 | marketbeat.com

TWST vs. NTRA: Which Genomics Play Is a Better Buy?

July 25, 2025 | 247wallst.com

Cwm LLC Has $639,000 Stake in Twist Bioscience Corporation (NASDAQ:TWST)

July 24, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) Position Trimmed by Jennison Associates LLC

July 21, 2025 | marketbeat.com

Bank of New York Mellon Corp Has $21.25 Million Stake in Twist Bioscience Corporation (NASDAQ:TWST)

July 18, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) Shares Bought by New York State Common Retirement Fund

July 17, 2025 | marketbeat.com

Principal Financial Group Inc. Trims Holdings in Twist Bioscience Corporation (NASDAQ:TWST)

July 17, 2025 | marketbeat.com

Twist Bioscience: Still Not There Yet

July 15, 2025 | seekingalpha.com

Twist Bioscience to Report Fiscal 2025 Third Quarter Financial Results on Monday, August 4, 2025

July 14, 2025 | businesswire.com

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis Sells 2,449 Shares

July 11, 2025 | marketbeat.com

Emily M. Leproust Sells 476 Shares of Twist Bioscience Corporation (NASDAQ:TWST) Stock

July 8, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH, BEAM, ARWR, and TWST Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.93 +0.13 (+0.82%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$15.70 -0.23 (-1.48%)

As of 08/1/2025 07:32 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Beam Therapeutics NASDAQ:BEAM

$18.83 -0.88 (-4.46%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$18.98 +0.15 (+0.80%)

As of 08/1/2025 07:58 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Theravance Biopharma NASDAQ:TBPH

$10.90 -0.26 (-2.33%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$10.90 -0.01 (-0.05%)

As of 08/1/2025 04:04 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Twist Bioscience NASDAQ:TWST

$33.68 +0.11 (+0.33%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$33.98 +0.30 (+0.89%)

As of 08/1/2025 06:52 PM Eastern

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time